Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Veracyte, Inc.    VCYT

VERACYTE, INC.

(VCYT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • The group usually releases upbeat results with huge surprise rates.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 24.66 USD
Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • The company has insufficient levels of profitability.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart
Sector Bio Diagnostics & Testing
1st jan.Capitalisation (M$)Investor Rating
VERACYTE, INC.2.31%1 395
GUARDANT HEALTH, INC.4.33%7 655
GENSCRIPT BIOTECH CORPORATI..-1.69%4 214
IOVANCE BIOTHERAPEUTICS, IN..-17.99%2 865
-
INVITAE CORPORATION14.69%1 786
MIRACA HOLDINGS INC.2.74%1 428
CAREDX, INC0.37%919
SEEGENE INC--.--%728
INNATE PHARMA12.58%582
LYSOGENE184.30%77
EPIGENOMICS AG2.20%67
More Results
Financials (USD)
Sales 2019 120 M
EBIT 2019 -11,2 M
Net income 2019 -9,07 M
Finance 2019 197 M
Yield 2019 -
P/E ratio 2019 -143x
P/E ratio 2020 -134x
EV / Sales2019 9,97x
EV / Sales2020 8,73x
Capitalization 1 395 M
Upcoming event on VERACYTE, INC.
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation -
Finances -
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes